Cargando…

Pseudomonas aeruginosa serotypes in nosocomial pneumonia: prevalence and clinical outcomes

INTRODUCTION: Pseudomonas aeruginosa frequently causes nosocomial pneumonia and is associated with poor outcome. The purpose of this study was to assess the prevalence and clinical outcome of nosocomial pneumonia caused by serotype-specific P. aeruginosa in critically ill patients under appropriate...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Qin, Eggimann, Philippe, Luyt, Charles-Edouard, Wolff, Michel, Tamm, Michael, François, Bruno, Mercier, Emmanuelle, Garbino, Jorge, Laterre, Pierre-François, Koch, Holger, Gafner, Verena, Rudolf, Michael P, Mus, Erkan, Perez, Antonio, Lazar, Hedvika, Chastre, Jean, Rouby, Jean-Jacques
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4057348/
https://www.ncbi.nlm.nih.gov/pubmed/24428878
http://dx.doi.org/10.1186/cc13697
_version_ 1782320947353616384
author Lu, Qin
Eggimann, Philippe
Luyt, Charles-Edouard
Wolff, Michel
Tamm, Michael
François, Bruno
Mercier, Emmanuelle
Garbino, Jorge
Laterre, Pierre-François
Koch, Holger
Gafner, Verena
Rudolf, Michael P
Mus, Erkan
Perez, Antonio
Lazar, Hedvika
Chastre, Jean
Rouby, Jean-Jacques
author_facet Lu, Qin
Eggimann, Philippe
Luyt, Charles-Edouard
Wolff, Michel
Tamm, Michael
François, Bruno
Mercier, Emmanuelle
Garbino, Jorge
Laterre, Pierre-François
Koch, Holger
Gafner, Verena
Rudolf, Michael P
Mus, Erkan
Perez, Antonio
Lazar, Hedvika
Chastre, Jean
Rouby, Jean-Jacques
author_sort Lu, Qin
collection PubMed
description INTRODUCTION: Pseudomonas aeruginosa frequently causes nosocomial pneumonia and is associated with poor outcome. The purpose of this study was to assess the prevalence and clinical outcome of nosocomial pneumonia caused by serotype-specific P. aeruginosa in critically ill patients under appropriate antimicrobial therapy management. METHODS: A retrospective, non-interventional epidemiological multicenter cohort study involving 143 patients with confirmed nosocomial pneumonia caused by P. aeruginosa. Patients were analyzed for a period of 30 days from time of nosocomial pneumonia onset. Fourteen patients fulfilling the same criteria from a phase IIa studyconducted at the same time/centers were included in the prevalence calculations but not in the clinical outcome analysis. RESULTS: The prevalence of serotypes was: O6 (29%), O11 (23%), O10 (10%), O2 (9%), and O1 (8%). Serotypes with a prevalence of less than 5% were found in 13% of patients, 8% were classified as not typeable. Across all serotypes, 19% mortality, 70% clinical resolution, 11% clinical continuation, and 5% clinical recurrence were recorded. Age and higher APACHE II (Acute Physiology and Chronic Health Evaluation II) were predictive risk factors associated with probability of death and lower clinical resolution for P. aeruginosa nosocomial pneumonia. Mortality tends to be higher with O1 (40%) and lower with O2 (0%); clinical resolution tends to be better with O2 (82%) compared to other serotypes. Persisting pneumonia with O6 and O11 was, respectively, 8% and 21%; clinical resolution with O6 and O11 was, respectively, 75% and 57%. CONCLUSIONS: In P. aeruginosa nosocomial pneumonia, the most prevalent serotypes were O6 and O11. Further studies including larger group sizes are needed to correlate clinical outcome with virulence factors of P. aeruginosa in patients with nosocomial pneumonia caused by various serotypes; and to compare O6 and O11, the two serotypes most frequently encountered in critically ill patients.
format Online
Article
Text
id pubmed-4057348
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40573482014-06-14 Pseudomonas aeruginosa serotypes in nosocomial pneumonia: prevalence and clinical outcomes Lu, Qin Eggimann, Philippe Luyt, Charles-Edouard Wolff, Michel Tamm, Michael François, Bruno Mercier, Emmanuelle Garbino, Jorge Laterre, Pierre-François Koch, Holger Gafner, Verena Rudolf, Michael P Mus, Erkan Perez, Antonio Lazar, Hedvika Chastre, Jean Rouby, Jean-Jacques Crit Care Research INTRODUCTION: Pseudomonas aeruginosa frequently causes nosocomial pneumonia and is associated with poor outcome. The purpose of this study was to assess the prevalence and clinical outcome of nosocomial pneumonia caused by serotype-specific P. aeruginosa in critically ill patients under appropriate antimicrobial therapy management. METHODS: A retrospective, non-interventional epidemiological multicenter cohort study involving 143 patients with confirmed nosocomial pneumonia caused by P. aeruginosa. Patients were analyzed for a period of 30 days from time of nosocomial pneumonia onset. Fourteen patients fulfilling the same criteria from a phase IIa studyconducted at the same time/centers were included in the prevalence calculations but not in the clinical outcome analysis. RESULTS: The prevalence of serotypes was: O6 (29%), O11 (23%), O10 (10%), O2 (9%), and O1 (8%). Serotypes with a prevalence of less than 5% were found in 13% of patients, 8% were classified as not typeable. Across all serotypes, 19% mortality, 70% clinical resolution, 11% clinical continuation, and 5% clinical recurrence were recorded. Age and higher APACHE II (Acute Physiology and Chronic Health Evaluation II) were predictive risk factors associated with probability of death and lower clinical resolution for P. aeruginosa nosocomial pneumonia. Mortality tends to be higher with O1 (40%) and lower with O2 (0%); clinical resolution tends to be better with O2 (82%) compared to other serotypes. Persisting pneumonia with O6 and O11 was, respectively, 8% and 21%; clinical resolution with O6 and O11 was, respectively, 75% and 57%. CONCLUSIONS: In P. aeruginosa nosocomial pneumonia, the most prevalent serotypes were O6 and O11. Further studies including larger group sizes are needed to correlate clinical outcome with virulence factors of P. aeruginosa in patients with nosocomial pneumonia caused by various serotypes; and to compare O6 and O11, the two serotypes most frequently encountered in critically ill patients. BioMed Central 2014-01-15 2014 /pmc/articles/PMC4057348/ /pubmed/24428878 http://dx.doi.org/10.1186/cc13697 Text en © Lu et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Lu, Qin
Eggimann, Philippe
Luyt, Charles-Edouard
Wolff, Michel
Tamm, Michael
François, Bruno
Mercier, Emmanuelle
Garbino, Jorge
Laterre, Pierre-François
Koch, Holger
Gafner, Verena
Rudolf, Michael P
Mus, Erkan
Perez, Antonio
Lazar, Hedvika
Chastre, Jean
Rouby, Jean-Jacques
Pseudomonas aeruginosa serotypes in nosocomial pneumonia: prevalence and clinical outcomes
title Pseudomonas aeruginosa serotypes in nosocomial pneumonia: prevalence and clinical outcomes
title_full Pseudomonas aeruginosa serotypes in nosocomial pneumonia: prevalence and clinical outcomes
title_fullStr Pseudomonas aeruginosa serotypes in nosocomial pneumonia: prevalence and clinical outcomes
title_full_unstemmed Pseudomonas aeruginosa serotypes in nosocomial pneumonia: prevalence and clinical outcomes
title_short Pseudomonas aeruginosa serotypes in nosocomial pneumonia: prevalence and clinical outcomes
title_sort pseudomonas aeruginosa serotypes in nosocomial pneumonia: prevalence and clinical outcomes
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4057348/
https://www.ncbi.nlm.nih.gov/pubmed/24428878
http://dx.doi.org/10.1186/cc13697
work_keys_str_mv AT luqin pseudomonasaeruginosaserotypesinnosocomialpneumoniaprevalenceandclinicaloutcomes
AT eggimannphilippe pseudomonasaeruginosaserotypesinnosocomialpneumoniaprevalenceandclinicaloutcomes
AT luytcharlesedouard pseudomonasaeruginosaserotypesinnosocomialpneumoniaprevalenceandclinicaloutcomes
AT wolffmichel pseudomonasaeruginosaserotypesinnosocomialpneumoniaprevalenceandclinicaloutcomes
AT tammmichael pseudomonasaeruginosaserotypesinnosocomialpneumoniaprevalenceandclinicaloutcomes
AT francoisbruno pseudomonasaeruginosaserotypesinnosocomialpneumoniaprevalenceandclinicaloutcomes
AT mercieremmanuelle pseudomonasaeruginosaserotypesinnosocomialpneumoniaprevalenceandclinicaloutcomes
AT garbinojorge pseudomonasaeruginosaserotypesinnosocomialpneumoniaprevalenceandclinicaloutcomes
AT laterrepierrefrancois pseudomonasaeruginosaserotypesinnosocomialpneumoniaprevalenceandclinicaloutcomes
AT kochholger pseudomonasaeruginosaserotypesinnosocomialpneumoniaprevalenceandclinicaloutcomes
AT gafnerverena pseudomonasaeruginosaserotypesinnosocomialpneumoniaprevalenceandclinicaloutcomes
AT rudolfmichaelp pseudomonasaeruginosaserotypesinnosocomialpneumoniaprevalenceandclinicaloutcomes
AT muserkan pseudomonasaeruginosaserotypesinnosocomialpneumoniaprevalenceandclinicaloutcomes
AT perezantonio pseudomonasaeruginosaserotypesinnosocomialpneumoniaprevalenceandclinicaloutcomes
AT lazarhedvika pseudomonasaeruginosaserotypesinnosocomialpneumoniaprevalenceandclinicaloutcomes
AT chastrejean pseudomonasaeruginosaserotypesinnosocomialpneumoniaprevalenceandclinicaloutcomes
AT roubyjeanjacques pseudomonasaeruginosaserotypesinnosocomialpneumoniaprevalenceandclinicaloutcomes